In Acute migraine headache Elipran 40 Tablet helps improve the flow of blood in your brain and prevents abnormal activity of muscles that triggers migraines. It is a very effective medicine for treating migraine attacks. By preventing and reducing the frequency migraine attacks, the medicine can help you carry out your daily activities and improve your quality of life.
Elipran 40 Tablet may cause excessive drowsiness with alcohol.
Elipran 40 Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Elipran 40 Tablet is safe to use during breastfeeding. Human studies suggest that the drug does not pass into the breastmilk in a significant amount and is not harmful to the baby. Limited information indicates that Elipran 40 Tablet produces low levels in milk and would not be expected to cause any adverse effects in breastfed infants.
Elipran 40 Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Elipran 40 Tablet should be used with caution in patients with kidney disease. Dose adjustment of Elipran 40 Tablet may be needed. Please consult your doctor. Use of Elipran 40 Tablet is not recommended in patients with severe kidney disease.
Elipran 40 Tablet should be used with caution in patients with severe liver disease. Dose adjustment of Elipran 40 Tablet may be needed. Please consult your doctor. Limited information is available on the use of Elipran 40 Tablet in these patients. No dose adjustment is recommended in patients with mild to moderate liver disease.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More